摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

去甲基三尖杉酮碱 | 51020-45-2

中文名称
去甲基三尖杉酮碱
中文别名
——
英文名称
demethylcephalotaxinone
英文别名
desmethylcephalotaxinone;(6S)-3-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,13,15(19)-tetraen-4-one
去甲基三尖杉酮碱化学式
CAS
51020-45-2
化学式
C17H17NO4
mdl
——
分子量
299.326
InChiKey
FDWVASNYLQYPMN-KRWDZBQOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    517.8±50.0 °C(Predicted)
  • 密度:
    1.49±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 储存条件:
    室温

SDS

SDS:1b3ebb1b30f0363b5d278a4ede15678d
查看

制备方法与用途

去甲基头孢噻酮是一种生物碱,在海南苏铁(C. hainanensis)中可以分离得到去甲基头孢噻酮类化合物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of AntiproliferativeCephalotaxus Esters and Their Evaluation against Several Human Hematopoietic and Solid Tumor Cell Lines: Uncovering Differential Susceptibilities to Multidrug Resistance
    作者:Joseph D. Eckelbarger、Jeremy T. Wilmot、Matthew T. Epperson、Chandar S. Thakur、David Shum、Christophe Antczak、Leonid Tarassishin、Hakim Djaballah、David Y. Gin
    DOI:10.1002/chem.200701998
    日期:2008.5.9
    isolated from the Cephalotaxus genus. Convergent syntheses of these four natural products are described, each involving novel synthetic methods and strategies. These syntheses enabled evaluation of several advanced natural and non-natural compounds against an array of human hematopoietic and solid tumor cells. Potent cytotoxicity was observed in several cell lines previously not challenged with these
    据报道,脱氧三尖杉酯碱 (2)、高三尖杉酯碱 (3)、高脱氧三尖杉酯碱 (4) 和脱水三尖杉酯碱 (5) 是从三尖杉属分离的抗白血病生物碱中最有效的成员。描述了这四种天然产物的收敛合成,每一种都涉及新的合成方法和策略。这些合成使得能够针对一系列人类造血和实体肿瘤细胞评估几种先进的天然和非天然化合物。在先前未用这些生物碱攻击的几种细胞系中观察到强细胞毒性。该生物碱家族内酯链结构的变化赋予了针对长春新碱抗性 HL-60/RV+ 的不同活性谱,为这些天然产物的分子设计以对抗多药耐药性提供了新的途径。
  • 一种手性(-)-三尖杉碱的合成方法及其中间体
    申请人:中国科学院上海有机化学研究所
    公开号:CN109776506B
    公开(公告)日:2022-06-21
    本发明公开了一种手性(‑)‑三尖杉碱的合成方法及其中间体。本发明的合成方法包括如下步骤:在溶剂中,在路易斯酸的作用下,将化合物A进行如下所示的重排反应得到化合物B即可。本发明的合成方法以工业化原料呋喃为起始原料,通过10步得到手性的三尖杉碱,反应收率高,操作简便,有望应用于工业生产。
  • Gold(I)-Catalyzed Cyclization–3-Aza-Cope–Mannich Cascade and Its Application to the Synthesis of Cephalotaxine
    作者:Takeo Sakai、Chise Okumura、Masatoshi Futamura、Naotaka Noda、Akari Nagae、Chiharu Kitamoto、Madoka Kamiya、Yuji Mori
    DOI:10.1021/acs.orglett.1c01323
    日期:2021.6.4
    The discovery of a new gold(I)-catalyzed cascade reaction involving cyclization onto a vinylammonium, 3-aza-Cope rearrangement, and Mannich cyclization is reported. A variety of fused nitrogen heterocycles were prepared from simple cyclic tertiary amines using 1–5 mol % of a AuCl(PPh3)/Ag[C5(CN)5] cocatalyst system. The developed reaction was used in a study aimed at synthesizing cephalotaxine. A five-step
    据报道,发现了一种新的金 (I) 催化级联反应,包括环化到乙烯基铵、3-氮杂-科普重排和曼尼希环化。使用 1–5 mol% 的 AuCl(PPh 3 )/Ag[C 5 (CN) 5 ] 助催化剂体系,从简单的环状叔胺制备了多种稠氮杂环。开发的反应用于旨在合成头孢噻肟的研究中。来自去甲肼苯哒嗪的五步操作以 39.1% 的总收率提供了去甲基头孢噻吩,其分两步转化为 (-)-头孢噻肟。
  • Desmethylcephalotaxinone and its correlation with cephalotaxine
    作者:Richard G. Powell Kenneth L.^Mikolajczak
    DOI:10.1016/0031-9422(73)80520-5
    日期:1973.12
    Abstract A new alkaloid, desmethylcephalotaxinone (IIIa) has been isolated from Cephalotaxus harringtonia (Forbes) K. Koch var. harringtonia cv. Fastigiata. Its structure has been established by spectral methods and by a partial synthesis from cephalotaxine (Ia) via cephalotaxinone (II). Methylation of IIIa with dimethoxypropane yields II along with some isocephalotaxinone (IIIb). Compound II was confirmed
    摘要 从 Cephalotaxus harringtonia (Forbes) K. Koch var. 中分离出一种新的生物碱去甲基头孢菌素 (IIIa)。哈灵顿 cv. 法斯蒂亚塔。其结构已通过光谱方法和头孢噻肟 (Ia) 经头孢菌素 (II) 部分合成确定。IIIa 与二甲氧基丙烷的甲基化产生 II 以及一些异头孢菌素 (IIIb)。化合物 II 被确认为天然存在的次要三尖杉成分。用硼氢化钠还原 II 立体定向地得到 Ia。
  • CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF
    申请人:Gin David
    公开号:US20110071097A1
    公开(公告)日:2011-03-24
    The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer.
    本发明提供了新型的头孢松酯、其合成方法以及中间体。本发明还提供了包括本发明化合物的药物组合物,以及使用该化合物或组合物治疗增生性疾病(例如良性肿瘤、癌症、炎症性疾病、自身免疫疾病、糖尿病性视网膜病变)和传染病的方法。本发明还提供了使用该化合物或组合物治疗多药耐药癌症的方法。
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine